Lead Product(s): AZ-3102
Therapeutic Area: Genetic Disease
Highest Development Status: Undisclosed Product Type: Small molecule
Deal Size: $28.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing February 06, 2020
The financing helps Azafaros to build its organization and expand its executive team with passionate and experienced people and to advance its rare metabolic disorders pipeline.